Table 2. Clinicopathological features of cHL cases stratified by clonal hematopoiesis distribution in the tissue.

N=40 patients		Clonal hematopoiesis in cHL tissue		Pb
		Extensivea (n=3)	Absent/non-extensive (n=37)
Age	>60 years	1 (33%)	9 (24%)	1
	<60 years	2 (67%)	28 (76%)
EBV Status	EBV+	1 (33%)	8 (22%)	0.55
	EBV-	2 (67%)	29 (78%)
Histotype	Nodular sclerosis	1 (33%)	21 (57%)	0.58c
	Mixed cellularity	2 (67%)	12 (32%)
	Other	0 (0%)	4 (11%)
Clinical stage	Early (≤ IIA)	1 (33%)	13 (37%)d	1
	Advanced (≥ IIB)	2 (67%)	22 (63%)d
Outcome of first-line therapye	No progression	0 (0%)	24 (69%)f	0.043
	Progression	3 (100%)	11 (31%)f
	Follow-up in monthsg	0-6-35	64 (median)g	0.034
			0-149 (range)g

^aExtensive: VAF≥10%.

^bBy Fisher exact test, except for comparison of follow-up where T-test was used.

^cNodular sclerosis vs all other subtypes.

^dClinical stage at diagnosis was not available for two patients (UPN26 and UPN40).

^eABVD in all cases, with the following exceptions of little relevance: i) COPP/ABV in pediatric patient UPN27, not showing clonal hematopoiesis and not progressing after first-line therapy; ii) COPP without vincristine in elderly patient UPN41/case 3, whose outcome was not evaluable; and iii) omission of bleomycin in 3/35 patients (UPN13, UPN25/case 4, and UPN30, all not showing extensive clonal hematopoiesis in the cHL tissue and all not progressing after first-line therapy). COPP/ABV stands for cyclophosphamide, vincristine sulfate, prednisone, procarbazine hydrochloride/doxorubicin hydrochloride, bleomycin, vinblastine sulfate.

^fOutcome was not available for one patient (UPN40), and was not evaluable in another patient (UPN41/case 3) who died early due to acute chemotherapy toxicity.

^gFollow-up was not available for one patient (UPN40), and not evaluable in another (UPN41/case 3).